SENTARA COMMUNITY PLAN
(MEDICAID)

MEDICAL PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: **The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request**. All other information may be filled in by office staff; **fax to 1-844-305-2331**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If information provided is not complete, correct, or legible, authorization can be delayed**.

Drug Requested: Entyvio® IV (vedolizumab) **(J3380) (Medical)**

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member Sentara #: _____ **Date of Birth:** _____

Prescriber Name: _____

Prescriber Signature: _____ **Date:** _____

Office Contact Name: _____

Phone Number: _____ **Fax Number:** _____

DEA OR NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Form/Strength: _____

Dosing Schedule: _____ **Length of Therapy**: _____

Diagnosis: _____ **ICD Code, if applicable:** _____

Weight: _____ **Date:** _____

❑ Standard Review. In checking this box, the timeframe does not jeopardize the life or health of the member or the member's ability to regain maximum function and would not subject the member to severe pain.

For Crohn's disease or Ulcerative Colitis: IV – 300mg at 0, 2, and 6 weeks for induction (3 vials/6 weeks) and then 300mg (1 vial) every 8 weeks thereafter the induction period. Discontinue therapy in patients who show no evidence of therapeutic benefit by week 14.

Off-label dosing: _____

Please submit literature and progress notes for off-label dosing.

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

❑ **Prescriber is a Gastroenterologist**

(Continued on next page)

DIAGNOSIS: Check diagnosis that applies.	
❑ **Crohn's Disease**	❑ **Ulcerative Colitis**:

❑ Member has trial and failure of a compliant regimen of oral corticosteroids (budesonide 9mg daily for 8 weeks) or high dose steroids (40-60 mg prednisone) (moderate to severe CD) unless contraindicated or intravenous corticosteroids (severe and fulminant CD or failure to respond to oral corticosteroids)

AND

❑ Member tried and failed **at least ONE previous 5-Aminosalicylates or Immunomodulators therapy below:**

❑ methotrexate	❑ azathioprine	❑ auranofin
❑ sulfasalazine	❑ oral aminosalicylates	❑ leflunomide
❑ 6-mercaptopurine	❑ Apriso®	❑ balsalazide
❑ Pentasa®		

AND

❑ Member has tried and failed: ❑ Humira® **AND** ❑ Infliximab

Medication being provided by: Please check applicable box below.

❑ **Location/site of drug administration:** _____

NPI or DEA # of administering location: _____

OR

❑ **Specialty Pharmacy – PropriumRx**

For urgent reviews: Practitioner should call Sentara Health Pre-Authorization Department if they believe a standard review would subject the member to adverse health consequences. Sentara Health's definition of urgent is a lack of treatment that could seriously jeopardize the life or health of the member or the member's ability to regain maximum function.

Use of samples to initiate therapy does not meet step edit/preauthorization criteria.

Previous therapies will be verified through pharmacy paid claims or submitted chart notes.*